India EBITDA margin expansion
150-200 bps
+150-200 bps YoY
Second consecutive quarter of margin expansion from payor mix and robotic surgeries.
NARAYANAHRUDAYALAYA
Other
10 Feb 2026
Narayana Hrudayalaya Ltd — Q3 FY26
Narayana Hrudayalaya reported a strong Q3 FY26, driven by India business margin expansion of 150-200 bps YoY from payor mix optimization, robotic surgeries, and technology infusion.
✓ Verified against BSE filing
2-Min Summary
Narayana Hrudayalaya reported a strong Q3 FY26, driven by India business margin expansion of 150-200 bps YoY from payor mix optimization, robotic surgeries, and technology infusion. Bangalore cluster led growth, while North faced softness due to scheme payer caps and competition. Cayman insurance losses widened despite revenue growth, but management expects underwriting focus from Q4. UK acquisition (Practice Plus) contributed 2 months, with EBITDA margins at 8.5-9% pre-IFRS; Birmingham hospital losses are expected to narrow within 4 quarters. India like-to-like growth is sustainable until new hospitals (900 beds in Bangalore, Kolkata health city) come online. Key risk: increased competition in Gurgaon and North Bangalore may pressure occupancy and realizations.
Key Numbers
UK EBITDA margin (pre-IFRS)
8.5-9%
flat
Practice Plus base business margin; Birmingham losses are dilutive but expected to reduce.
Cayman hospital revenue
$45M
flat
Revenue run-rate; local market share still below government hospital.
UK acquisition debt
£150M
flat
Debt at SONIA+200bps; 2-year interest-only then 5-year equal principal repayment.
Management Guidance
India like-to-like revenue growth sustainable
Management expects double-digit revenue growth from existing hospitals to continue until new hospitals are commissioned, barring major adverse events.
revenueIndia margins to be maintained at current levels
Efforts will continue to sustain the margin expansion seen in the last two quarters, though no specific guidance is given.
marginsCayman insurance focus shift to underwriting
From Q4 onwards, focus will be on improving underwriting performance and optimizing the book rather than aggressive growth.
growthUK acquisition expected to be EPS neutral
Management expects the UK acquisition to be EPS neutral to mildly positive for the group, excluding one-time deal costs.
otherKey Risks
Increased competition in North Bangalore and Gurgaon
New hospitals coming up in these regions may pressure occupancy and realizations, especially in Gurgaon where competition is already intense.
high · analyst_questionCayman insurance loss ratio volatility
Large claims can cause quarterly swings in insurance losses; management acknowledged unpredictability quarter-on-quarter.
medium · management_commentaryUK integration and margin improvement timeline
While early results are expected soon, full realization of operational efficiencies and payer mix improvement may take longer, with no specific timeline given.
medium · analyst_questionNorth India cluster softness due to scheme payer caps
Conscious volume reduction in scheme patients due to reimbursement caps and increased competition has led to slower growth in the North cluster.
medium · management_commentaryNotable Quotes
We have been a bit cognizant on the receivable problems in some of the scheme payers and also on the capping on reimbursement of certain drugs which has actually resulted in a conscious call in controlling volumes on the schemes.
Our view on Gurgaon Delhi Hospital profitability aspects and ability to fill the beds from a competition viewpoint giving multiple large players are expanding already and have an existing presence. That has been our biggest challenge.
We do believe that the UK acquisition will deliver reasonably strong ROCEs for us. It's a leveraged buyout, it's an asset-light model.